Inadequate immune responses force Merck to abandon COVID-19 vaccines


Merck, one of the world's most storied vaccine makers, is abandoning the development of its two COVID-19 vaccines after initial trials resulted in inadequate immune responses, Stat News reports. Both vaccines produced lower levels of coronavirus antibodies than have been found in the blood of individuals who recovered from natural COVID-19 infections. For reference, the Pfizer-BioNTech and Moderna vaccines produced antibody levels several times higher than natural infections.
The unsuccessful trials are disappointing in large part because both Merck vaccines would have required just one dose, writes Stat. One of the candidates, which uses the same virus as the one in Merck's successful Ebola vaccine, was being developed in partnership with the International AIDS Vaccine Initiative, which has said it will try to determine if using an oral or intranasal administration route will work better than the current intramuscular injection. It's unclear if Merck will continue to collaborate — IAVI's president Mark Feinberg told Stat he hopes they do — because the pharmaceutical company has suggested it will now turn its focus to developing COVID-19 therapeutics.
As Stat notes, the results show just how difficult vaccine development can be, especially in such a short amount of time, making the rapid success of the Pfizer-BioNTech and Moderna shots seem all the more remarkable. Read more at Stat News.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
The student loans fraud scandal
The Explainer Huge amounts of money may have been fraudulently claimed from the Student Loans Company
By Sorcha Bradley, The Week UK Published
-
Is this the end of democracy in Turkey?
Today's Big Question President Erdoğan's jailing of political rival a 'decisive moment' that moves country toward full-fledged autocracy
By Elliott Goat, The Week UK Published
-
How the government's welfare reforms could affect you
The Explainer Labour is attempting to balance the books with £5bn of benefits cuts
By Marc Shoffman, The Week UK Published
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published